SCHEMBL21802

SCHEMBL21802

FC1(F)[CH]C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2146311 1.00
SCHEMBL478015 0.70
SCHEMBL424149 0.70
SCHEMBL14118553 0.65
SCHEMBL360654 0.63
SCHEMBL6216231 0.62
SCHEMBL15427989 0.60
SCHEMBL4528642 0.60
SCHEMBL3324872 0.60
SCHEMBL9438183 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5396 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228468-A1 N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS VANDERBILT UNIVERSITY 2024-07-11 US claimed
EP-4392032-A1 MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME Arena Pharmaceuticals, Inc. (US) 2024-07-03 EP claimed
EP-4387970-A1 SUBSTITUTED 1,2,4-THIADIAZOLYL NICOTINAMIDES, SALTS OR N-OXIDES THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES Bayer Aktiengesellschaft (DE) 2024-06-26 EP claimed
CN-118159536-A Substituted 1,2, 4-thiadiazolyl nicotinamide, salts or N-oxides thereof and their use as herbicidal active substances 拜耳公司 2024-06-07 CN claimed
WO-2024118887-A1 N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA BLUEPRINT MEDICINES CORPORATION (US) 2024-06-06 WO claimed
US-20240174655-A1 INDAZOLE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2024-05-30 US claimed
WO-2024108147-A1 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-05-23 WO claimed
WO-2024089155-A1 HETEROCYCLIC COMPOUNDS AS STING ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-02 WO claimed
US-20240140919-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2024-05-02 US claimed
US-11970485-B2 RET kinase inhibitors ELI LILLY AND COMPANY (US) 2024-04-30 US claimed
US-4362728-A Haloguanidine compounds, pharmaceutical compositions and methods of use ICI AMERICAS INC. (US) 1982-12-07 US claimed
EP-0065823-A1 Heterocyclic guanidines as histamine H-2 antagonists IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-12-01 EP claimed
EP-0061318-A2 Guanidinoheterocyclic derivatives as histamine H-2 antagonists IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-29 EP claimed
EP-0060697-A1 Heterocyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-22 EP claimed
EP-0060730-A2 Bicyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-22 EP claimed
EP-0060696-A1 Nitrogen heterocycles IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-22 EP claimed
EP-0060094-A2 Guanidine derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-15 EP claimed
EP-0059597-A2 Guanidino-substituted heterocyclic derivatives having histamine H-2 antagonist activity IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-08 EP claimed
EP-0045155-A1 Guanidine derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-02-03 EP claimed
EP-0030092-A1 Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1981-06-10 EP claimed